BMJ. 1991 Jan 26;302(6770):210-6. doi: 10.1136/bmj.302.6770.210.
To compare the efficacy of angiotensin converting enzyme inhibition with calcium antagonism in diabetic patients with microalbuminuria.
Randomised study of diabetic patients with microalbuminuria treated with perindopril or nifedipine for 12 months and monitored for one or three months after stopping treatment depending on whether they were hypertensive or normotensive. Patients were randomised separately according to whether they were hypertensive or normotensive.
Diabetic clinics in three university teaching hospitals.
50 diabetic patients with persistent microalbuminuria. In all, 43 completed the study: 30 were normotensive and 13 hypertensive; 19 had type I diabetes and 24 had type II diabetes.
For 12 months 20 patients were given perindopril 2-8 mg daily and 23 were given nifedipine 20-80 mg daily.
Albumin excretion rate, blood pressure, and glomerular filtration rate.
Both perindopril and nifedipine significantly reduced mean blood pressure. During treatment there was no significant difference between those treated with perindopril and those treated with nifedipine with respect to albuminuria or mean blood pressure. Stopping treatment with both drugs was associated with a sustained increase in albuminuria and mean blood pressure. There was a significant correlation between mean blood pressure and albuminuria and also between the reduction in mean blood pressure and the decrease in albuminuria during treatment with both drugs. In hypertensive patients both drugs caused significant decreases in mean blood pressure and albuminuria. In normotensive patients there was no significant reduction in albuminuria with either regimen.
In diabetic patients with microalbuminuria blood pressure seems to be an important determinant of urinary albumin excretion. Perindopril and nifedipine have similar effects on urinary albumin excretion, both preventing increases in albuminuria in normotensive patients and decreasing albuminuria in hypertensive patients.
比较血管紧张素转换酶抑制剂与钙拮抗剂对糖尿病微量白蛋白尿患者的疗效。
对糖尿病微量白蛋白尿患者进行随机研究,用培哚普利或硝苯地平治疗12个月,根据患者是否高血压,在停药后监测1个月或3个月。患者根据是否高血压分别进行随机分组。
三家大学教学医院的糖尿病诊所。
50例持续性微量白蛋白尿的糖尿病患者。共有43例完成研究:30例血压正常,13例高血压;19例为I型糖尿病,24例为II型糖尿病。
20例患者每日服用培哚普利2 - 8毫克,共12个月;23例患者每日服用硝苯地平20 - 80毫克,共12个月。
白蛋白排泄率、血压和肾小球滤过率。
培哚普利和硝苯地平均显著降低平均血压。治疗期间,培哚普利治疗组和硝苯地平治疗组在蛋白尿或平均血压方面无显著差异。两种药物停药后均伴有蛋白尿和平均血压持续升高。两种药物治疗期间,平均血压与蛋白尿之间以及平均血压降低与蛋白尿减少之间均存在显著相关性。在高血压患者中,两种药物均导致平均血压和蛋白尿显著下降。在血压正常的患者中,两种治疗方案均未使蛋白尿显著降低。
在糖尿病微量白蛋白尿患者中,血压似乎是尿白蛋白排泄重要的决定因素。培哚普利和硝苯地平对尿白蛋白排泄有相似的作用,均能防止血压正常患者蛋白尿增加,并降低高血压患者的蛋白尿。